Pregnancy and Inflammatory Rheumatological Diseases: A Single-Center Retrospective Cohort Study.

Autor:	Alkhodier AA; College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, SAU., Alsaif AS; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU., Alqntash NH; Clinical Sciences, Princess Nourah bint Abdulrahman University College of Medicine, Riyadh, SAU., Alanazi RB; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU., Alotaibi G; Pathology, King Khalid University Hospital, King Saud University, Riyadh, SAU., Alrashid A; Rheumatology, King Abdulaziz Medical City, Riyadh, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Oct 18; Vol. 15 (10), pp. e47277. Date of Electronic Publication: 2023 Oct 18 (Print Publication: 2023).
DOI:	10.7759/cureus.47277
Abstrakt:	Background Rheumatic diseases pose risks to pregnant women, leading to complications like preterm birth, congenital heart block, and pregnancy loss. These diseases are expected to deteriorate during pregnancy and further in the postpartum period. The impact of these diseases on the pregnancy will add further burden on the patient, fetus, physician, and healthcare system. Advances in diagnosis and treatment have improved outcomes making them similar to that of healthy women, but close follow-up in a multidisciplinary clinic is essential. The objective of this study is to study the outcome of pregnancy in women with rheumatological disease and the behavior of the disease during pregnancy. Methods A retrospective cohort study was conducted in King Abdulaziz Medical City (KAMC) in Riyadh, Saudi Arabia, to compare the outcomes of pregnancy across three rheumatological diseases: Sjogren syndrome (SS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) from 2016 to 2021. A total of 128 pregnancies in 107 women with rheumatological diseases were included in this study. Pregnancy measures and outcomes were investigated by assessing maternal health, fetal health, and pregnancy complications, specifically maternal disease activity, medications to control the disease, infection, preterm birth, birth weight, abortions/stillbirths, mode of delivery, bleeding, preeclampsia, congenital heart block, and neonatal lupus. Results There were 55 patients with RA (63 RA pregnancies), 44 with SLE (54 SLE pregnancies), and eight with primary SS (11 SS pregnancies). In most of the pregnancies (n= 108; 95.58%), the patients were in clinical remission before pregnancy. Lupus nephritis, which was in remission before pregnancy, has been reported in nine (16.67%) out of 54 SLE pregnancies. Vaginal delivery was the most common mode of delivery (n=87; 67.97%). On the other hand, there were 38 cesarean sections (29.69%). Rheumatological disease flares occurred in 10 pregnancies (7.87%). One hundred and twenty-two live births were delivered. Preterm infants were born in 25 pregnancies (20.16%), and 16 (13.22%) of the newborns needed neonatal intensive care unit (NICU) care. Interestingly, congenital heart block (CHB) was found in five (12.2%) neonates out of 41 anti-SS-related antigen A (anti-SSA) positive mothers; one of those five died from heart block. Eleven neonates were delivered with positive serology, and five were diagnosed with neonatal lupus. Conclusion The outcome of pregnancy in patients with rheumatological disease is favorable. A multidisciplinary team approach and close clinical follow-up are the cornerstone for such success. A small dose of prednisolone (5 mg or less) is safe and will not have a negative impact on maternal or fetal health. CHB is a concern for pregnant women with positive anti-SSA. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Alkhodier et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu